DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A•••• A• F•••• P•• L••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Also written as: Aspen Pharmacare
Principal held
at least $258M
sum of BDC pieces, a lower bound
Fair value
$168M
97c on cost, debt pieces
Unfunded
$10.8M
commitments not yet drawn
BDC lenders
3
3 on the latest quarter
Facilities
3
0 equity pieces beside them
Next maturity
May 27, 2033
no dated debt inside 24 months
On the tape since
Mar 31, 2026
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $139M | 97c | //www.goldmansachsbdc.com/20260630#Bank Bill Swap Bid Rate BBSY+475 bp | May 27, 2033 | 1 |
| other lien unstated | at least $119M | 97c | S+475 bp | May 27, 2033 | 2 |
| delayed draw term loan lien unstated | unknown | n/a | unstated | 2 |
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| B••••••••• P•••••• C••••• F••• | delayed draw term loan lien unstated D•••••• D••• T••• L••• | n/a | n/a | |
| B••••••••• P•••••• C••••• F••• | unstated lien unstated N••••••••• I••••• | $119M | $81.4M 97c | S+475 bp |
| B••••••••• S•••••• L•••••• F••• | unstated lien unstated N••••••••• I••••• | $167,000 | $100,000 92c | S+475 bp |
| B••••••••• S•••••• L•••••• F••• | delayed draw term loan lien unstated D•••••• D••• T••• L••• | n/a | n/a | |
| G•••••• S•••• P•••••• C••••• C•••• | term loan first lien 1st L•••/S••••• S•••••• D••• I••••••• P••••••••• R•••••••• R••• and S••••• B + 4.75% M•••• | $13.3M | $-46,000 98c | //www.goldmansachsbdc.com/20260630#Bank Bill Swap Bid Rate BBSY+475 bp |
| G•••••• S•••• P•••••• C••••• C•••• | term loan first lien 1st L•••/S••••• S•••••• D••• I••••••• P••••••••• I••••••• R••• 9.24% R•••••••• R••• and S• | $125M | $85.5M 97c | //www.goldmansachsbdc.com/20260630#Bank Bill Swap Bid Rate BBSY+475 bp |
| G•••••• S•••• P•••••• C••••• C•••• | term loan first lien 1st L•••/S••••• S•••••• D••• I••••••• P••••••••• I••••••• R••• 9.24% R•••••••• R••• and S• | $1.2M | $850,000 97c | //www.goldmansachsbdc.com/20260630#Bank Bill Swap Bid Rate BBSY+475 bp |
| G•••••• S•••• P•••••• C••••• C•••• | term loan first lien 1st L•••/S••••• S•••••• D••• I••••••• P••••••••• R•••••••• R••• and S••••• BY + 4.75% M••• | $155,000 | $-1,000 100c | //www.goldmansachsbdc.com/20260630#Bank Bill Swap Bid Rate BBSY+475 bp |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3 | $258M | $168M | 97c | 0 |
| Mar 31, 2026 | 1 | $177M | $0 | n/a | 0 |
What changed
- New borrower on a BDC scheduleMar 31, 2026
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- APPLE AUderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 3 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it